The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCTEA.L Regulatory News (CTEA)

  • There is currently no data for CTEA

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half-year Report

29 Sep 2023 07:00

RNS Number : 0792O
Catenae Innovation PLC
29 September 2023
 

29 September 2023

Catenae Innovation PLC

("Catenae", the "Company" or the "Group")

 

Half Year Results

Convertible Loan Update

 

 

Catenae Innovation PLC (AIM: CTEA), the AIM quoted provider of digital media and technology, announces its half-yearly report for the six months ended 30 June 2023.

 

As this is the first six months since the change of the year-end to 31 December, comparative figures are for the six months to 31 March 2022.

 

Financial overview

 

· Loss of £185,267 in the period under review (2022: £287,168) with revenues of £22,173 (2022: £17,500).

· Net (liability)/asset position £(314,846) (2022: £110,033).

 

Post period end

 

· As announced on 6 September 2023, the Company's 51% subsidiary ceased trading due to losses incurred.

 

The Company continues to carefully manage its working capital position.

 

Convertible Loan Update

 

As announced on 30 September 2022, the Company entered into an agreement for a convertible loan facility for up to £250,000 ("Convertible Loan") with Sanderson Capital Partners Limited ("Sanderson Capital"), which consists of an initial drawdown of £125,000 followed by a further drawdown expected three months thereafter.

 

As at 30 June 2023, an advance of £30,000 had been received against the £125,000 and no shares or warrants issued. As at 28 September 2023, a total advance of £61,000 had been received against the £125,000 and no shares or warrants have been issued.

 

At each £125,000 drawdown, the Company will issue new ordinary shares to Sanderson Capital equal to 10 percent of the drawdown value at an issue price of the 10-day volume weighted average price prior to the date of drawdown. A further announcement will be made on the date of each drawdown event.

 

Sanderson Capital will be able to convert part or all of the Convertible Loan facility in minimum increments of £5,000, with the conversion price being fixed at the lower of i) 0.25p; or ii) 90% of the 5-day volume weighted average price from the first day of dealings of the Company's restoration to trading on AIM. The Convertible Loan facility is interest-free.

 

As part of the Convertible Loan facility agreement, Sanderson Capital will be issued new ordinary shares and a warrant over new ordinary shares in the Company, of which the issue price and exercise price is 0.25 pence per share, being the closing mid-price of the Company's ordinary shares on 30 September 2022, the first day of dealings following the release of the Company's final results for the year ended 30 September 2021, and the interim results for the period ended 31 March 2022 which enabled the lifting of the suspension and restoration to trading of the Company's ordinary shares on AIM.

 

The new ordinary shares and warrants over new ordinary shares will be issued after the next general meeting of the Company and a further announcement setting out the details will be made at the time of issue.

 

This announcement contains inside information for the purposes of the UK Market Abuse Regulation. The person who arranged for release of this announcement on behalf of the Company was Guy Meyer, Chief Executive Officer of the Company and the Directors of the Company are responsible for the release of this announcement.

 

 

For further information please contact:

 

Catenae Innovation PLC

+44 (0)191 580 8545

Guy Meyer, Chief Executive Officer

Cairn Financial Advisers LLP (Nominated Adviser)

+44(0)20 7213 0880

Liam Murray / Jo Turner

Shard Capital Partners LLP (Broker)

+44 (0)20 7186 9952

Damon Heath

 

 

 

Notes to Editors:

 

About Catenae Innovation PLC

Catenae Innovation is an AIM quoted provider of digital media and technology services. The Company specialises in Distributed Ledger Technology solutions that solve commercial challenges and create opportunities for its clients. The Company has an experienced IT team of project managers and integrators who have deployed systems across corporate, government and educational sectors.

 

www.catenaeinnovation.com

 

 

 

 

Consolidated Statement of Comprehensive Income

For the Period Ended 30 June 2023

 

 

Unaudited

six months ended

30 June

2023

 

£

Unaudited

six months ended

31 March

2022

 

£

Audited

year

ended

31 December

2022

 

£

 

Revenue

 

22,173

 

17,500

 

152,437

 

Cost of sales

 

(2,315)

 

(6,000)

 

(12,600)

 

Gross profit

 

19,858

 

11,500

 

139,837

 

Administrative expenses

 

(205,125)

 

(298,668)

 

(667,002)

 

 

 

Loss from operations

 

(185,267)

 

(287,168)

 

(527,165)

 

Net Finance income/(expense)

 

-

 

-

 

-

 

 

Loss before taxation

 

(185,267)

 

(287,168)

 

(527,165)

 

Taxation

 

-

 

-

 

3,668

 

Total comprehensive loss for the year

 

(185,267)

 

(287,168)

 

(523,497)

 

 

Loss attributable to:

 

 

Owners of the parent

(183,023)

(280,260)

(514,695)

Non-controlling interest

(2,244)

(6,908)

(8,802)

 

 

 

 

Consolidated Statement of Financial Position

 For the Period Ended 30 June 2023 

 

 

Unaudited

six months

ended

30 June

2023

 

£

Unaudited

six months

ended

31 March

2022

 

£

Audited

year

ended

31 December

2022

 

£

Non-current assets

 

 

 

Tangible Assets

4,345

6,518

5,431

Intangible assets

1

1

1

4,346

6,519

5,432

 

Current assets

 

 

Trade and other receivables

17,893

30,514

81,913

Cash and cash equivalents

2,015

337,183

65,443

19,908

367,697

147,356

Current liabilities

Trade and other payables

(339,100)

(264,183)

(279,086)

(339,100)

(264,183)

(279,086)

 

 

 

Non-current liabilities

 

 

 

Interest-bearing loans

-

-

-

Total Liabilities

(339,100)

(264,183)

(279,086)

 

 

 

Net Assets/(Liabilities)

(314,846)

110,033

(126,298)

Non-controlling Interest

472

4,611

2,716

 

Capital and reserves attributable to equity holders of the company

Ordinary share capital

570,078

570,078

570,078

Deferred share capital

3,159,130

3,159,130

3,159,130

Share premium account

19,665,457

19,665,457

19,665,457

Share reserve

(83,333)

(83,333)

(83,333)

Merger reserve

11,119,585

11,119,585

11,119,585

Capital Redemption Reserve

2,732,904

2,732,904

2,732,904

Retained losses

(37,479,139)

(37,058,399)

(37,292,835)

 

Total Equity

 

(314,846)

 

110,033

 

(126,298)

 

 

 

 

 

 

 

 

Consolidated Statement of Cash Flows

For the Period Ended 30 June 2023 

 

Unaudited

six months

ended

30 June 2023

 

£

Unaudited

six months

ended

31 March 2022

 

£

Audited

year

ended

31 Dec 2022

 

£

 

Loss for the period

 

(185,267)

 

(287,168)

 

(523,497)

Adjustments for:

Impairment of investments

-

-

-

Depreciation

1,086

-

1,810

 

Net (loss) before changes in working capital

 

 

(184,181)

 

 

(287,168)

 

 

(521,687)

(Increase) / decrease in trade and other receivables

 

64,019

 

15,034

 

(36,677)

(Decrease) / increase in trade and other

payables

 

56,734

 

(11,038)

 

3,865

 

Cash from operations

 

(63,428)

 

(283,172)

 

(554,499)

 

Interest received

 

-

 

-

 

-

Interest paid

-

-

-

Net cash flows from operating activities

 

(63,428)

 

(283,172)

 

(554,499)

 

Investing activities

 

 

 

Purchase of plant and equipment

-

-

(413)

Net cash flows from investing activities

 

-

 

-

 

(413)

 

Financing Activities

 

Issue of ordinary share capital

-

15,273

15,273

Repayment of loans

-

-

-

New loans raised

-

-

-

Net cash flows from financing activities

 

-

 

15,273

 

15,273

 

Net increase / (decrease) in cash

 

(63,428)

 

(267,899)

 

(539,639)

Cash and cash equivalents at beginning of period

 

65,443

 

605,082

 

605,082

Cash and cash equivalents at end of period

 

2,015

 

337,183

 

65,443

 

Company Statement of Financial Position

For the Period Ended 30 June 2023

 

 

Unaudited

six months

ended

30 June

2023

 

£

Unaudited

six months

ended

31 March

2022

£

Audited

year

ended

31 December

2022

 

£

Non-current assets

 

 

 

Intangible assets

1

1

1

1

1

1

 

Current assets

 

 

Trade and other receivables

13,864

24,242

74,745

Cash and cash equivalents

99

332,209

61,922

13,963

356,451

136,667

Current liabilities

Trade and other payables

(366,493)

(255,828)

(308,508)

(366,493)

(255,828)

(308,508)

 

 

 

Non-current liabilities

 

 

 

Interest-bearing loans

-

-

-

Total Liabilities

(366,493)

(255,828)

(308,508)

 

 

 

Net Assets/(Liabilities)

(352,529)

100,624

(171,840)

 

Capital and reserves attributable to equity holders of the company

Ordinary share capital

570,078

570,078

570,078

Deferred share capital

3,159,130

3,159,130

3,159,130

Share premium account

19,665,457

19,665,457

19,665,457

Share reserve

(83,333)

(83,333)

(83,333)

Merger reserve

11,119,585

11,119,585

11,119,585

Capital Redemption Reserve

2,732,904

2,732,904

2,732,904

Retained losses

(37,516,350)

(37,063,197)

(37,335,661)

 

Total Equity

 

(352,529)

 

100,624

 

(171,840)

 

 

 

 

 

 

 

 

 

Company Statement of Cash Flows

For the Period Ended 30 June 2023 

 

Unaudited

six months

ended

30 June 2023

 

£

Unaudited

six months

ended

31 March 2022

 

£

Audited

year

ended

31 Dec 2022

 

£

 

Loss for the period

 

(180,690)

 

(273,069)

 

(545,533)

Adjustments for:

Impairment of investment

 

-

 

Net (loss) before changes in working capital

 

 

(180,690)

 

 

(273,069)

 

 

(545,533)

(Increase) / decrease in trade and other receivables

 

60,882

 

20,995

 

(29,509)

(Decrease) / increase in trade and other

payables

 

57,985

 

29,168

 

81,849

 

Cash from operations

 

(61,823)

 

(222,906)

 

(493,193)

 

Interest received

 

-

 

-

 

-

Interest paid

-

-

-

Net cash flows from operating activities

 

(61,823)

 

(222,906)

 

(493,193)

 

Financing Activities

 

Issue of ordinary share capital

-

15,273

15,273

Repayment of loans

-

-

-

New loans raised

-

-

-

Net cash flows from financing activities

 

-

 

15,273

 

15,273

 

Net increase / (decrease) in cash

 

(61,823)

 

(207,633)

 

(477,920)

Cash and cash equivalents at beginning of period

 

61,922

 

539,842

 

539,842

Cash and cash equivalents at end of period

 

99

 

332,209

 

61,922

 

 

 

 

 

 

 

 

 

 

 

Caution regarding forward looking statements

 

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identi?ed by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements re?ect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR FLFIAAIITFIV
Date   Source Headline
1st Jul 20203:12 pmRNSTotal Voting Rights
1st Jul 20202:06 pmRNSSecond Price Monitoring Extn
1st Jul 20202:00 pmRNSPrice Monitoring Extension
1st Jul 20207:00 amRNSCompletion of Cov-ID Project
30th Jun 20207:01 amRNSHalf-year Report
30th Jun 20207:00 amRNSFinal Results
26th Jun 20204:30 pmRNSExercise of Warrant
23rd Jun 20204:41 pmRNSSecond Price Monitoring Extn
23rd Jun 20204:36 pmRNSPrice Monitoring Extension
19th Jun 20207:00 amRNSCov-ID Project Update
12th Jun 20209:58 amRNSIssue of Equity
11th Jun 20202:02 pmRNSShare Price Movement and Update
10th Jun 202012:30 pmRNSExercise of Warrant, Conversion & Issue of Equity
3rd Jun 20207:00 amRNSHolding(s) in Company
3rd Jun 20207:00 amRNSHolding(s) in Company
3rd Jun 20207:00 amRNSHolding(s) in Company
29th May 202012:24 pmRNSHolding(s) in Company
29th May 20207:00 amRNSAgreement with Newcastle Premier Health Ltd
28th May 20204:41 pmRNSSecond Price Monitoring Extn
28th May 20204:35 pmRNSPrice Monitoring Extension
21st May 20207:00 amRNSExercise of Warrant and Issue of Equity
18th May 20207:00 amRNSCov-ID Project Update
14th May 202012:49 pmRNSResult of General Meeting and Issue of Equity
1st May 20209:00 amRNSUpdate - Cov-ID Project
29th Apr 20205:09 pmRNSPosting of Circular and Notice of General Meeting
28th Apr 20204:41 pmRNSSecond Price Monitoring Extn
28th Apr 20204:35 pmRNSPrice Monitoring Extension
24th Apr 20207:00 amRNSDirectorate Changes
23rd Apr 202012:19 pmRNSHolding(s) in Company
21st Apr 20202:05 pmRNSSecond Price Monitoring Extn
21st Apr 20202:00 pmRNSPrice Monitoring Extension
20th Apr 20203:32 pmRNSConditional Placing to raise £320,000 and Update
17th Apr 20207:00 amRNSCatenae joins Consortium on Cov-ID Project
16th Apr 20205:30 pmRNSChange of Broker
31st Mar 20202:45 pmRNSHolding(s) in Company
31st Mar 20202:40 pmRNSHolding(s) in Company
31st Mar 20202:35 pmRNSHolding(s) in Company
31st Mar 20207:00 amRNSAnnual Report, Trading & COVID-19 Update
26th Mar 202012:49 pmRNSWorking Capital Facility
31st Jan 20201:36 pmRNSIssue of Equity & Proposed Directorate Change
24th Jan 20201:20 pmRNSUpdate re Working Capital & Balance Sheet
10th Jan 202012:23 pmRNSUpdate re Working Capital & Balance Sheet
23rd Dec 201911:37 amRNSResult of General Meeting
20th Dec 20195:02 pmRNSUpdate re Working Capital
20th Dec 20191:23 pmRNSFurther re Share Capital & Timetable Update
20th Dec 20197:00 amRNSShare Capital and Total Voting Rights
19th Dec 20197:00 amRNSFurther re Agreements and update
6th Dec 201910:53 amRNSPosting of Circular and Notice of General Meeting
12th Sep 201910:50 amRNSHolding(s) in Company
11th Sep 20197:30 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.